Skip to main content

Crescent Biopharma, Inc.

corporate_fare Company Profile

Crescent Biopharma, Inc.

CBIO·NASDAQ·Life Sciences·CIK 0001253689

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing therapies for people with cancer. The company was incorporated in Delaware in 2003 and, on June 16, 2025, changed its jurisdiction of incorporation to the Cayman Islands. It operates through two distinct strategies to build its portfolio. First, it is developing CR-001, a PD-1 x VEGF bispecific antibody designed to bind both the PD-1 immune checkpoint and Vascular Endothelial Growth Factor. This product has the potential to replace pembrolizumab, marketed as Keytruda®, as a foundational immuno-oncology treatment. A global Phase 1/2 trial of CR-001, known as the ASCEND trial, was initiated in February 2026. Second, the company is building a portfolio of antibody drug conjugates (ADCs). The company intends to combine CR-001 and ADC therapies. It anticipates initiating CR-002 and CR-003 monotherapy clinical trials in 2026, as well as the first ADC combination trial with CR-001 in the same year.

Crescent Biopharma, Inc. (NASDAQ:CBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CBIO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Resale Prospectus Filed for 19.7M Shares, Representing Over 70% of Outstanding Equity, Creating Significant Market Overhang
  • Selling Securityholders Register Resale of 19.7M Shares, Representing Over 70% of Outstanding Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$10.84M
Net Income
-$153.94M
Op. Cash Flow
-$71.53M
Free Cash Flow
-$72.45M
Operating Income
-$152.63M
Cash & Equivalents
$213.19M
Debt / Equity
0.00×
Net Margin
-14.20×
Shares Outstanding
27.56M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-011983
$13
52-week range · as of 2026-11-12 $8.72 – $27.41
Market cap
$505.64M
Volume
422.4K (1.7× avg)
3-mo avg 246K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CBIO - Filings & News (Page 2)

CBIO
Jan 15, 2026, 5:04 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $13.55
Real-time Price: $13.00 info
Change: -$0.545 (-4%) info
Market Cap: $505.641M info
CBIO
Jan 07, 2026, 5:08 PM EST
Filing Type: S-1
Importance Score:
9
Price at Filing: $10.80
Real-time Price: $13.00 info
Change: +$2.20 (+20%) info
Market Cap: $505.641M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets